December 6, 2017 07:28 AM EST
Bioregnum
Opinion

Af­ter build­ing ex­pec­ta­tions, the UK’s life sci­ences plan falls short of the hype

Mer­ck’s re­cent an­nounce­ment of a new re­search cen­ter in Lon­don like­ly whet­ted the UK life sci­ences sec­tor’s ap­petite for even big­ger news from the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

GSK sues Mod­er­na over mR­NA vac­cine patents, seeks 'rea­son­able roy­al­ty'

J&J trims pipeline, in­clud­ing two mid-stage neu­ro­science stud­ies

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

Mary­land biotech gets green light for stem cell-de­rived ther­a­py for di­a­betes, aim­ing to com­pete with Ver­tex

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times